Ascenta Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to discovering and developing new medicines to stop cancer. Our core technology consists of agents designed to re-establish the natural program of apoptosis that shuts down cell growth and proliferation in abnormal cells. We have a compound in Phase II cancer clinical trials that inhibits the Bcl-2 family of proteins and a pipeline that targets Bcl-2, MDM2 and XIAP. Our development team has broad and deep expertise in oncology and is focused exclusively on addressing the unique obstacles and complex challenges cancer brings to drug development.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 04/01/07 | Series C | 50M | Unknown |
People
Mel Sorensen (President/CEO)
Dajun Yang (SVP Research)
Lance Leopold (Chief Medical Officer)
Ming Guo (VP Manufacturing)
Joel Sussman (CFO)
View more details about all 12 people at Ascenta Therapeutics
News
Heathcare venture funding surges in first quarter
April 23, 2007 5:00 am
Biotechnology and medical-device venture investment soared in the first quarter as funding for information technology and other sectors declined, according… Continue reading ⟩